Todd Wider
Director/Board Member at ARYA SCIENCES ACQUISITION CORP IV
Net worth: 2 M $ as of 2024-04-29
Todd Wider active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ARYA SCIENCES ACQUISITION CORP IV | Director/Board Member | 2021-02-28 | - |
| Independent Dir/Board Member | 2021-02-28 | - | |
| ARYA SCIENCES ACQUISITION CORP V | Director/Board Member | 2021-06-30 | - |
| Independent Dir/Board Member | 2021-06-30 | - | |
| ASP ISOTOPES INC. | Director/Board Member | 2021-09-30 | - |
| Independent Dir/Board Member | 2021-09-30 | - | |
| GENENTA SCIENCE S.P.A. | Director/Board Member | 2024-05-01 | - |
Emendo Biotherapeutics, Inc.
 Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | Chairman | 2018-05-31 | - |
| Chief Tech/Sci/R&D Officer | 2018-05-31 | - | |
| Wider Film Projects | Corporate Officer/Principal | - | - |
Varian Biopharmaceuticals, Inc.
 Varian Biopharmaceuticals, Inc. BiotechnologyHealth Technology Part of Healthtech Solutions, Inc., Varian Biopharmaceuticals, Inc. is a private precision oncology company based in Naples, FL. Varian Bio is developing novel therapeutics for the treatment of cancer using precision oncology, which involves DNA testing to identify genetic mutations in tumors for more targeted treatment recommendations. Varian Bio's lead drug candidate, Var-101, is being developed in a topical formulation for the treatment of basal cell carcinoma, while Var-102, an oral formulation, is being developed for the treatment of various solid tumors, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Varian Bio is also seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. The CEO of the company is Jeffrey Blaine Davis. Varian Biopharmaceuticals was acquired by Healthtech Solutions, Inc. on May 07, 2021. | Director/Board Member | - | - |
| Xanadu Bio Inc. | Director/Board Member | - | - |
| Founder | - | - |
Career history of Todd Wider
Former positions of Todd Wider
| Companies | Position | Start | End |
|---|---|---|---|
| ARYA SCIENCES ACQUISITION III A | Director/Board Member | 2020-07-31 | 2021-05-31 |
| Independent Dir/Board Member | 2020-07-31 | 2021-05-31 | |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░ ░░░░░░░░ ░░░░░░░░░░░ ░░░ ░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Training of Todd Wider
| Princeton University | Undergraduate Degree |
| Columbia University College of Physicians & Surgeons | Doctorate Degree |
Statistics
International
| United States | 15 |
| Italy | 2 |
Operational
| Director/Board Member | 11 |
| Independent Dir/Board Member | 7 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 6 |
| Finance | 6 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
| ABEONA THERAPEUTICS INC. | Health Technology |
| GENENTA SCIENCE S.P.A. | Health Technology |
| ARYA SCIENCES ACQUISITION CORP IV | Finance |
| ASP ISOTOPES INC. | Health Technology |
| Private companies | 9 |
|---|---|
ARYA Sciences Acquisition Corp.
 ARYA Sciences Acquisition Corp. Financial ConglomeratesFinance ARYA Sciences Acquisition Corp. is an organized blank check company, which engages in effecting a merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination with one or more entities. The company was founded by Joseph Eric Edelman, Adam Stone and Michael Altman in June 2018 and is headquartered in New York, NY. | Finance |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | Health Technology |
ARYA Sciences Acquisition Corp. II
 ARYA Sciences Acquisition Corp. II Financial ConglomeratesFinance ARYA Sciences Acquisition Corp. II is blank check company which formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which refer to as its initial business combination. The company was founded by Joseph Edelman, Adam Stone & Michael Altman on February 20, 2020 and is headquartered in New York, NY. | Finance |
Lyfebulb LLC
 Lyfebulb LLC Internet Software/ServicesTechnology Services Lyfebulb LLC is an innovation accelerator that works with patient communities and the healthcare industry to generate insights and build new solutions to reduce the burden of living with chronic disease. The private company is based in New York, NY. The company operates across 12 disease states and has two digital patient communities, including ibdlyfe. The company's mission is to reduce the burden of living with chronic disease through the power of the patient. Lyfebulb was founded by Riccardo Braglia, Stephen P. Squinto, and Karin M. Hehenberger, who has been the CEO since incorporation. | Technology Services |
| Wider Film Projects | |
ARYA Sciences Acquisition Corp. III
 ARYA Sciences Acquisition Corp. III Financial ConglomeratesFinance ARYA Sciences Acquisition Corp III is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which it refers to as its initial business combination. It has not yet selected any business combination target. The company was founded by Joseph Edelman, Adam Stone, Michael Altman, and Konstantin Poukalov on March 27, 2020 and is headquartered in New York, NY. | Finance |
Varian Biopharmaceuticals, Inc.
Varian Biopharmaceuticals, Inc. BiotechnologyHealth Technology Part of Healthtech Solutions, Inc., Varian Biopharmaceuticals, Inc. is a private precision oncology company based in Naples, FL. Varian Bio is developing novel therapeutics for the treatment of cancer using precision oncology, which involves DNA testing to identify genetic mutations in tumors for more targeted treatment recommendations. Varian Bio's lead drug candidate, Var-101, is being developed in a topical formulation for the treatment of basal cell carcinoma, while Var-102, an oral formulation, is being developed for the treatment of various solid tumors, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Varian Bio is also seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. The CEO of the company is Jeffrey Blaine Davis. Varian Biopharmaceuticals was acquired by Healthtech Solutions, Inc. on May 07, 2021. | Health Technology |
ARYA Sciences Acquisition Corp. V
 ARYA Sciences Acquisition Corp. V Financial ConglomeratesFinance Arya Sciences Acquisition Corp. V is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Adam Stones, Joseph Eric Edelman, Michael R. Altman, and Konstantin Poukalov on February 22, 2021 and is headquartered in New York, NY. | Finance |
| Xanadu Bio Inc. |
- Stock Market
- Insiders
- Todd Wider
- Experience
